Trend
DailyUptrend (confirmed)
4 hourStrong Bearish
1 hourLeaning Bullish
15 minBullish
5 minStrong Bearish
Daily trend turns down below $25.87
Key levels
Resistance$30.10
Resistance$25.87
Support$20.78
Support$17.84
Latest news & SEC filings
AnalystPiper Sandler keeps Neutral rating on Caris Life Sciences, lifts target to $25
DealEDX Medical strikes product deal with Caris Life Sciences
NewsCaris Life Sciences publishes study on molecular profiling in ESR1-mutated metastatic breast cancer
All CAI news →Caris Life Sciences is a precision medicine company focused on cancer. It analyzes tissue and blood samples using genomic sequencing and computational methods to help guide treatment decisions. Its offerings include tissue-based profiling, blood-based profiling, and an early detection test in development. Customers include physicians, academic researchers, and pharmaceutical companies. It operates mainly in the United States.
Based on the company's 10-K filed Mar 3, 2026.
Nasdaq · Healthcare
SEPT Low Target
$25.00
SEPT Mid Target
$30.00
SEPT High Target
$38.00
Analyst Consensus
$30.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for CAI.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/E Forward, P/B, Analyst Consensus
Fair Value
$44.14
41
Moat Score
NARROW
5/9
Piotroski Score
3.2
Altman Z-Score
Insider Signal
SELLING
0 buys / 4 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Denton John Russel | officer | Sale | 7,500 | $239K | Sep 22, 2026 |
| Spetzler David Baxley | officer | Buy | 250,000 | $610K | Sep 4, 2026 |
| Spetzler David Baxley | officer | Sale | 119,212 | $3.0M | Sep 4, 2026 |
| Spetzler David Baxley | officer | Buy | 1,000,000 | $2.4M | Sep 3, 2026 |
| Spetzler David Baxley | officer | Sale | 393,100 | $9.7M | Sep 3, 2026 |
| Spetzler David Baxley | officer | Sale | 84,900 | $2.1M | Sep 3, 2026 |
| CASTLEMAN PETER M | director | Buy | 13,192 | - | Aug 14, 2026 |
| PHILLIPS T DANNY | director | Buy | 13,192 | - | Aug 14, 2026 |
| Gilliam Joseph E | director | Buy | 13,192 | - | Aug 14, 2026 |
| Vacirca Jeff L | director | Buy | 13,192 | - | Aug 14, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
97.0%
3yr Revenue CAGR
N/A%
EPS Growth YoY
69.79%
FCF Growth YoY
126.4%
Revenue Trend
ACCELERATING
SEPT Investing tracks real-time dark pool institutional trades for CAI, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:26:11 | $24.49 | 2,592 | $$63K | SELL |
| 21:26:00 | $24.49 | 20,281 | $$497K | SELL |
| 21:00:48 | $24.49 | 4,343 | $$106K | SELL |
| 21:00:47 | $24.49 | 1,900 | $$47K | SELL |
| 21:00:47 | $24.49 | 6,215 | $$152K | SELL |
5 dark pool trades shown · $$865K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT Investing provides real-time options flow tracking for CAI, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| PUT | $30 | Jan 15 | 65 | $$371.7K | 590 | BLOCK |
| PUT | $35 | Jan 15 | 65 | $$259.7K | 245 | BLOCK |
2 options trades shown · 0% calls
Unusual activity, GEX levels, max pain, and dealer positioning
SEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for CAI. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
Smart Money Moves $FMAO — Briggs Andrew J | Sale $106K $VG — Blake Sarah | Sale $1.6M $VG — Blake Sarah | Sale $14.0M $CAI — CASTLEMAN PETER M | Sale $CAI — PHILLIPS T DANNY | Sale
Smart Money Moves $FMAO — Briggs Andrew J | Sale $106K $VG — Blake Sarah | Sale $1.6M $VG — Blake Sarah | Sale $14.0M $CAI — CASTLEMAN PETER M | Sale $CAI — PHILLIPS T DANNY | Sale
Zone Setup -- $CAI (Caris Life Sciences, Inc.) Price: $15.58 | Zone: $15.18 to $15.95 Conviction: HIGH | Analyst upside: +89.9% Near resistance (52% of range) — breakout watch. Strong positive news ...
Join 3,500+ traders discussing CAI in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
SEPT's Trading AI has generated a free, downloadable PDF research report for Caris Life Sciences, Inc. (CAI) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Caris Life Sciences, Inc. (CAI) is at $23.96, down 2.16% (-$0.53) at the Nov 12, 2026 close.
Latest CAI news — Nov 10, 2026: Piper Sandler keeps Neutral rating on Caris Life Sciences, lifts target to $25 · Nov 10, 2026: EDX Medical strikes product deal with Caris Life Sciences
The average analyst price target for CAI is $30.00, ranging from $25 to $38, based on 9 analysts. Latest: Piper Sandler maintains on Nov 10, 2026.
Analyst ratings for CAI: 0 Buy, 14 Hold, 1 Sell — consensus Hold.
CAI last reported on Nov 4, 2026: EPS $0.05 vs $0.03 expected — a beat of 77.9%.
CAI trades at a P/E of 3.1 vs a Healthcare average of 17.1.
CAI does not currently pay a dividend.
Support: $20.78, $17.84, $15.11. Resistance: $25.87, $30.10, $32.89.
Insider activity: SELLING, 0 buys and 4 sells in the last 90 days.
Nov 10, 2026: Piper Sandler keeps Neutral rating on Caris Life Sciences, lifts target to $25 · Nov 10, 2026: EDX Medical strikes product deal with Caris Life Sciences · Nov 9, 2026: Caris Life Sciences publishes study on molecular profiling in ESR1-mutated metastatic breast cancer